Hypertriglyceridemia - Pipeline Review, H2 2016
SKU ID :GMD-10293768 | Published Date: 30-Dec-2016 | No. of pages: 113Description
TOC
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Hypertriglyceridemia Overview 9
Therapeutics Development 10
Pipeline Products for Hypertriglyceridemia - Overview 10
Pipeline Products for Hypertriglyceridemia - Comparative Analysis 11
Hypertriglyceridemia - Therapeutics under Development by Companies 12
Hypertriglyceridemia - Therapeutics under Investigation by Universities/Institutes 14
Hypertriglyceridemia - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Hypertriglyceridemia - Products under Development by Companies 18
Hypertriglyceridemia - Products under Investigation by Universities/Institutes 19
Hypertriglyceridemia - Companies Involved in Therapeutics Development 20
Acasti Pharma Inc 20
Akcea Therapeutics Inc 21
Allergan Plc 22
Alnylam Pharmaceuticals Inc 23
Arisaph Pharmaceuticals Inc 24
AstraZeneca Plc 25
BASF SE 26
Cardax Inc 27
Catabasis Pharmaceuticals Inc 28
Celon Pharma SA 29
CymaBay Therapeutics Inc 30
Gemphire Therapeutics Inc 31
Jeil Pharmaceutical Co Ltd 32
Kyorin Pharmaceutical Co Ltd 33
LipimetiX Development Inc 34
Matinas BioPharma Holdings Inc 35
Sancilio & Company Inc 36
Zydus Cadila Healthcare Ltd 37
Hypertriglyceridemia - Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Target 39
Assessment by Mechanism of Action 41
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 47
AEM-28 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
AEM-2814 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
ALN-AC3 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
ALN-ANG - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Antibody to Inhibit ANGPTL4 for Hypertriglyceridemia - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
ARI-3037MO - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
bezafibrate SR - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
BioE-1115 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
BSN-272 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
CAT-2000 Series - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
CAT-2003 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
CDX-085 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
gemcabene calcium - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
icosabutate - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
IONIS-ANGPTL3LRx - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
IONIS-APOCIIILRX - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
LTPO-3FA - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
MAT-9001 - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
MN-002 - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
NKPL-66 - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
omega-3-carboxylic acids - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
saroglitazar - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
SC-401 - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
seladelpar - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
Small Molecule for Hypertriglyceridaemia - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
Synthetic Peptides for Dyslipidemic and Vascular Disorders - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
volanesorsen sodium - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
Hypertriglyceridemia - Dormant Projects 97
Hypertriglyceridemia - Discontinued Products 99
Hypertriglyceridemia - Product Development Milestones 100
Featured News & Press Releases 100
Dec 19, 2016: Akcea and Ionis Announce Positive Results from COMPASS Phase 3 Study of Volanesorsen 100
Sep 14, 2016: Acasti Pharma Reports Positive CaPre Omega-3 Bridging Study Data 101
Jun 11, 2016: New Scientific Data of Investigational Lipaglyn (Saroglitazar), and Real World Data in Patients will be Featured at American Diabetes Association (ADA) 76th Scientific Sessions 102
May 16, 2016: Akcea Therapeutics Announces Completion of Enrollment in Phase 3 COMPASS Trial of Volanesorsen 103
Mar 23, 2016: MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia 103
Feb 24, 2016: SPCI Announces US PTO Allowance of Patent Claims 104
Nov 18, 2015: Zydus announces clinical trials of Saroglitazar in patients with Severe Hypertriglyceridemia in USA 104
Jul 29, 2015: Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine 105
May 25, 2015: Phase 2a Clinical Study of Icosabutate in Patients with Severe Hypertriglyceridemia 106
Apr 22, 2015: CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 in Severe Hypertriglyceridemia 107
Mar 02, 2015: Acasti Receives Full Data for Phase II TRIFECTA Trial 107
Sep 30, 2014: Acasti Announces Positive Top-Line Pharmacokinetic Results 108
Sep 29, 2014: Acasti Reports Successful CaPre Phase II TRIFECTA Results Proving Statistically Significant Improvements in Triglycerides & Non-HDL-C 108
Sep 02, 2014: Isis Pharmaceuticals Presents Data On ISIS-APOCIIIRX At European Society of Cardiology Congress 2014 110
Jul 24, 2014: Acasti Announces Oral Presentation on COLT Study Results at 19th World Congress on Heart Disease in Boston 110
Appendix 112
Methodology 112
Coverage 112
Secondary Research 112
Primary Research 112
Expert Panel Validation 112
Contact Us 112
Disclaimer 113
Tables & Figures
List of Tables
Number of Products under Development for Hypertriglyceridemia, H2 2016 10
Number of Products under Development for Hypertriglyceridemia - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Comparative Analysis by Late Stage Development, H2 2016 15
Comparative Analysis by Clinical Stage Development, H2 2016 16
Comparative Analysis by Early Stage Development, H2 2016 17
Products under Development by Companies, H2 2016 18
Products under Investigation by Universities/Institutes, H2 2016 19
Hypertriglyceridemia - Pipeline by Acasti Pharma Inc, H2 2016 20
Hypertriglyceridemia - Pipeline by Akcea Therapeutics Inc, H2 2016 21
Hypertriglyceridemia - Pipeline by Allergan Plc, H2 2016 22
Hypertriglyceridemia - Pipeline by Alnylam Pharmaceuticals Inc, H2 2016 23
Hypertriglyceridemia - Pipeline by Arisaph Pharmaceuticals Inc, H2 2016 24
Hypertriglyceridemia - Pipeline by AstraZeneca Plc, H2 2016 25
Hypertriglyceridemia - Pipeline by BASF SE, H2 2016 26
Hypertriglyceridemia - Pipeline by Cardax Inc, H2 2016 27
Hypertriglyceridemia - Pipeline by Catabasis Pharmaceuticals Inc, H2 2016 28
Hypertriglyceridemia - Pipeline by Celon Pharma SA, H2 2016 29
Hypertriglyceridemia - Pipeline by CymaBay Therapeutics Inc, H2 2016 30
Hypertriglyceridemia - Pipeline by Gemphire Therapeutics Inc, H2 2016 31
Hypertriglyceridemia - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2016 32
Hypertriglyceridemia - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2016 33
Hypertriglyceridemia - Pipeline by LipimetiX Development Inc, H2 2016 34
Hypertriglyceridemia - Pipeline by Matinas BioPharma Holdings Inc, H2 2016 35
Hypertriglyceridemia - Pipeline by Sancilio & Company Inc, H2 2016 36
Hypertriglyceridemia - Pipeline by Zydus Cadila Healthcare Ltd, H2 2016 37
Assessment by Monotherapy Products, H2 2016 38
Number of Products by Stage and Target, H2 2016 40
Number of Products by Stage and Mechanism of Action, H2 2016 42
Number of Products by Stage and Route of Administration, H2 2016 44
Number of Products by Stage and Molecule Type, H2 2016 46
Hypertriglyceridemia - Dormant Projects, H2 2016 97
Hypertriglyceridemia - Dormant Projects (Contd..1), H2 2016 98
Hypertriglyceridemia - Discontinued Products, H2 2016 99
List of Figures
Number of Products under Development for Hypertriglyceridemia, H2 2016 10
Number of Products under Development for Hypertriglyceridemia - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 16
Comparative Analysis by Early Stage Products, H2 2016 17
Assessment by Monotherapy Products, H2 2016 38
Number of Products by Top 10 Targets, H2 2016 39
Number of Products by Stage and Top 10 Targets, H2 2016 39
Number of Products by Top 10 Mechanism of Actions, H2 2016 41
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 41
Number of Products by Routes of Administration, H2 2016 43
Number of Products by Stage and Routes of Administration, H2 2016 43
Number of Products by Molecule Types, H2 2016 45
Number of Products by Stage and Molecule Types, H2 2016 45
Companies
Acasti Pharma Inc
Akcea Therapeutics Inc
Allergan Plc
Alnylam Pharmaceuticals Inc
Arisaph Pharmaceuticals Inc
AstraZeneca Plc
BASF SE
Cardax Inc
Catabasis Pharmaceuticals Inc
Celon Pharma SA
CymaBay Therapeutics Inc
Gemphire Therapeutics Inc
Jeil Pharmaceutical Co Ltd
Kyorin Pharmaceutical Co Ltd
LipimetiX Development Inc
Matinas BioPharma Holdings Inc
Sancilio & Company Inc
Zydus Cadila Healthcare Ltd
- PRICE
-
$2000$6000